Under construction – not a live service
Sign in
Taking people in SpainNo phase

Studies rare blood disorders to tailor future patient care

Uses detailed body and genetic testing in people with sickle cell and other rare anemias.

Plain-language title generated from the registry record
Registry title: Integrative Diagnosis for SCD and Other RADs

Key facts

Where
Barcelona, Esplugues de Llobregat, and Madrid, SpainSee the 4 sites

Where in Spain

  • Hospital de la Santa Creu i Sant PauBarcelona, SpainTaking people
  • Hospital Universitari Vall d'HebronBarcelona, SpainTaking people
  • Hospital Sant Joan De DeuEsplugues de Llobregat, SpainTaking people
  • Hospital General Universitari Gregorio MarañónMadrid, SpainTaking people

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?
Print a page for my doctor

Trial details

Who runs it
Hospital Universitari Vall d'Hebron Research Institute
Trial code
NCT07206095
Record updated
10 November 2026
Original description
INTEGRA aims at enabling personalized medicine for RADs patients by the establishment of an integrative diagnostic approach based on deep phenotypic and genetic characterization through combining new generation methodologies.Read full original descriptionShow less

Integrative Diagnosis of Sickle Cell Disease (SCD) and Other Rare Anemia Disorders (RADs) for Personalized Medicine

INTEGRA aims at enabling personalized medicine for RADs patients by the establishment of an integrative diagnostic approach based on deep phenotypic and genetic characterization through combining new generation methodologies.

Inclusion: Patients sustaining a confirmed or suspected diagnosis of an hereditary rare hemolytic anemia:; Sickle cell disease (SCD) Thalassaemia syndromes Congenital dyserythropoietic anaemia (CDA) Enzymopathies Unstable haemoglobin / altered oxygen affinity Hereditary stomatocytosis Hereditary pyropoikilocytosis; Hereditary spherocytosis (HS), either severe (baseline Hb <10 g/dL or transfusion-dependent) or with an inconclusive diagnosis:; Patient with chronic haemolytic anaemia and a compatible red cell smear, but with:; EMA binding test: inconclusive or negative Genetic testing: no definitive diagnosis (VUS or no findings).

Exclusion: Carrier traits in autosomal recessive hereditary anemias.

ClinicalTrials.gov NCT07206095